The Most Misunderstood Prostate Supplement
Saw palmetto (Serenoa repens) is the most commonly used herbal supplement for prostate health, with annual sales exceeding $200 million. It’s recommended by naturopaths, sold in every supplement store, and taken daily by millions of men over 40 who believe it’s protecting their prostate. What most of these men don’t realize is that saw palmetto’s mechanism of action — inhibiting 5-alpha reductase and blocking DHT — has implications for testosterone optimization that can work directly against their goals.
In my coaching practice, saw palmetto is one of the most common supplements I ask clients to reconsider. Not because it’s dangerous — it’s quite safe — but because many men are taking it without understanding the trade-offs involved, and those trade-offs matter significantly in the context of hormone optimization.
How Saw Palmetto Works
Saw palmetto contains liposterolic extracts — primarily fatty acids and phytosterols — that inhibit the enzyme 5-alpha reductase. This is the same enzyme targeted by pharmaceutical drugs finasteride and dutasteride. 5-alpha reductase converts testosterone to dihydrotestosterone (DHT), which is 3-5 times more potent at the androgen receptor than testosterone itself.
In the prostate, DHT drives cellular proliferation. Reducing DHT signaling in the prostate slows the growth of prostate tissue, potentially reducing symptoms of benign prostatic hyperplasia (BPH) — the age-related prostate enlargement that causes urinary symptoms in many men over 50. This is the intended therapeutic effect of saw palmetto.
However, saw palmetto’s 5-alpha reductase inhibition isn’t prostate-specific. It affects DHT levels throughout the body, which means it also impacts DHT-dependent tissues including hair follicles, sexual function, muscle, the nervous system, and skin. This systemic effect is a perfect example of the Tony Huge Laws of Biochemistry Physics in action: you cannot selectively inhibit a fundamental enzyme in one tissue without creating downstream hormonal consequences throughout the entire endocrine network.
The Clinical Evidence for Prostate Health
The evidence for saw palmetto’s effectiveness for BPH is surprisingly mixed despite its popularity. Early studies showed significant improvement in urinary symptoms. However, larger, more rigorous trials — including the STEP trial (Saw Palmetto Treatment for Enlarged Prostates) and the CAMUS trial — found no significant difference between saw palmetto and placebo for urinary symptom improvement, even at double and triple doses.
A Cochrane review concluded that saw palmetto provides mild to no benefit for BPH symptoms. This doesn’t mean it’s completely ineffective — individual variability in 5-alpha reductase expression and extract quality may explain the inconsistent results. But the robust clinical evidence doesn’t support the strong claims made by supplement manufacturers.
The Anti-Androgen Trade-Off
For men in the Natty Plus framework who are actively optimizing their androgen profile, saw palmetto’s DHT-reducing effect is potentially counterproductive. DHT isn’t just a “prostate growth hormone” — it has important functions throughout the male body.
DHT drives facial hair growth and masculine facial structure. It supports libido and sexual function (DHT is more potent than testosterone at androgen receptors in sexual tissues). It contributes to confidence and assertiveness through CNS androgen receptor activation. It supports muscle hardness and definition (though testosterone is more important for overall muscle mass). And it plays a role in neurological function and neuroprotection.
Men who significantly reduce DHT through saw palmetto (or finasteride/dutasteride) may experience decreased libido, erectile dysfunction, reduced facial hair growth, brain fog or cognitive changes, depression or emotional blunting, and reduced sexual sensitivity. These side effects parallel those reported with pharmaceutical 5-alpha reductase inhibitors, though saw palmetto’s effects are generally milder due to less potent enzyme inhibition.
Who Should and Shouldn’t Take Saw Palmetto
Saw palmetto may be appropriate for men over 50 with documented BPH symptoms (frequent urination, weak stream, nighttime waking to urinate) who have discussed the trade-offs with a knowledgeable physician and are willing to accept potential anti-androgenic effects in exchange for urinary symptom relief. For these men, saw palmetto’s mild 5-alpha reductase inhibition may provide modest symptom improvement with fewer side effects than pharmaceutical alternatives.
Saw palmetto is likely inappropriate for men actively optimizing testosterone and DHT through the Natty Plus Protocol, men under 40 without diagnosed BPH (taking it “preventively” is not supported by evidence), men experiencing low libido or sexual dysfunction (reducing DHT may worsen these symptoms), and men concerned about looksmaxxing or facial masculinization (DHT drives these effects).
Alternatives for Prostate Support
For men who want to support prostate health without reducing DHT, several alternatives exist. Lycopene from tomatoes has the strongest evidence for prostate cancer risk reduction without any anti-androgenic effects. Pumpkin seed oil provides zinc and fatty acids that support prostate health through anti-inflammatory mechanisms. Stinging nettle root may support prostate health while also reducing SHBG — a dual benefit. Adequate zinc intake supports prostate cellular function. Regular exercise, particularly aerobic exercise, is consistently associated with better prostate outcomes.
The Natty Plus approach to prostate health prioritizes these non-anti-androgenic interventions, reserving 5-alpha reductase inhibition (whether herbal or pharmaceutical) for men with diagnosed BPH who have weighed the full trade-off profile. The prostate matters, but so does the rest of the androgen-dependent physiology that makes men feel and function optimally.
Interesting Perspectives
While the primary narrative around saw palmetto focuses on prostate health, its mechanism invites unconventional analysis. Its role as a mild 5-alpha reductase inhibitor places it on the same biochemical spectrum as pharmaceutical finasteride, albeit with lower potency. This raises a provocative question: could low-dose saw palmetto be strategically used by individuals seeking to attenuate, rather than obliterate, DHT-related effects like scalp hair loss, without committing to the potential side-effect profile of stronger drugs? Some biohackers explore this as a “soft” intervention for androgenetic alopecia, though this is a significant deviation from its marketed purpose and still carries anti-androgen trade-offs.
Another emerging angle examines its potential anti-inflammatory and anti-estrogenic properties beyond DHT inhibition. Some research suggests its liposterolic extracts may interact with estrogen receptors and inflammatory pathways like COX-2, which could contribute to perceived benefits for urinary symptoms independently of significant DHT reduction. This aligns with the Tony Huge Laws of Biochemistry Physics, where a single plant extract exerts multiple, often unintended, receptor-level effects, creating a net outcome that is difficult to attribute to one pathway. For the hormone-aware individual, this polypharmacology is a double-edged sword: potential benefits are muddied by unpredictable systemic interactions.
Citations & References
- Barry, M. J., et al. (2011). “Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial.” JAMA, 306(12), 1344-1351. (The CAMUS trial).
- Tacklind, J., et al. (2012). “Serenoa repens for benign prostatic hyperplasia.” Cochrane Database of Systematic Reviews, (12). (Cochrane review).
- Avins, A. L., et al. (2009). “Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review.” JAMA, 299(15), 1704-1706.
- Wilt, T. J., et al. (2002). “Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review.” The Journal of the American Medical Association, 280(18), 1604-1609.
- Bent, S., et al. (2006). “Saw palmetto for benign prostatic hyperplasia.” New England Journal of Medicine, 354(6), 557-566. (The STEP trial).
- Scaglione, F., et al. (2008). “Comparison of the potency of different brands of Serenoa repens extract on 5α-reductase types I and II in prostatic co-cultured epithelial and fibroblast cells.” Pharmacology, 82(4), 270-275.
- Ishani, A., et al. (2006). “Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis.” The American Journal of Medicine, 119(9), 785-786.
- Habib, F. K., & Wyllie, M. G. (2004). “Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract.” Prostate Cancer and Prostatic Diseases, 7(3), 195-200.